Most diseases have multifactorial causes and hence require solutions that address the multiple mechanisms that contribute to disease initiation and progression.
Our combinatorial platform allows us to identify novel drugs that target multiple drivers of disease.
Using disease-specific screens we have identified unique combinations of botanical extracts that target the multiple contributing mechanisms of disease initiation and progression. Our lead compound, Epidiferphane, has demonstrated clinical and preclinical efficacy at preventing and treating several disease indications.
Prevention of negative side effects of chemotherapy
Anemia (low red blood cells)
Neutropenia (low white blood cells)
Chemofog (memory problems)
Management of arthritis
Reduce the inflammation and pain related to arthritis
Treatment of brain tumors
Adjunctive treatment aimed at slowing the progression of tumor growth
Prana Therapeutics was founded on a mission to develop combinatorial approaches to treating complex diseases. The company’s drug development program is based on pioneering research from the University of Florida.
Prana Therapeutics has an exclusive worldwide license to the technology and its commercialization.
Our lead compound, Epidiferphane, has demonstrated preclinical efficacy as a treatment to attenuate many of the negative side effects of chemotherapy (anemia, cytopenia, peripheral neuropathy, and chemofog), reduce inflammatory diseases (like rheumatoid arthritis) and helps slow the progression of tumor growth.